Tokyo: Japanese drugmaker Eisai Co Ltd and its US partner Biogen Inc said on Monday that the US Food and Drug Administration granted priority review for traditional approval of their Alzheimer’s treatment Lecanemab. The FDA accepted Eisai’s supplemental Biologics License Application for the drug, supporting the transition from the accelerated approval granted in January, the drugmaker said in a statement. Read all the Latest News, Trending News, Cricket News, Bollywood News, India News and Entertainment News here. Follow us on Facebook, Twitter and Instagram.
FDA grants priority review for Alzheimer's drug Lecanemab, say Eisai, Biogen
FDA grants priority review for Alzheimer's drug Lecanemab, say Eisai, Biogen
reuters
• March 6, 2023, 14:02:06 IST
The FDA accepted Eisai’s supplemental Biologics License Application for the drug, supporting the transition from the accelerated approval granted in January
read moreAdvertisement
 "FDA grants priority review for Alzheimer's drug Lecanemab, say Eisai, Biogen")
Find us on YouTube
 "It’s Pawwsible! The miracle drug that could extend your dog’s life")
 "Soon, doctors may be able to diagnose Alzheimer's using just a simple blood test")
 "World Alzheimer's Day 2023: Why caregivers of dementia patients need their stories to be heard")
 "Please Stand Up: Does sitting for more than 10 hours increase risk of dementia?")
 "It’s Pawwsible! The miracle drug that could extend your dog’s life")
 "Soon, doctors may be able to diagnose Alzheimer's using just a simple blood test")
 "World Alzheimer's Day 2023: Why caregivers of dementia patients need their stories to be heard")
 "Please Stand Up: Does sitting for more than 10 hours increase risk of dementia?")
Top Shows
